Loading...

Q BioMed Inc.

QBIO•PNK
Healthcare
Biotechnology
$0.00
$0.00(0.00%)

Q BioMed Inc. (QBIO) Stock Overview

Explore Q BioMed Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap14.5K
P/E Ratio-0.00
EPS (TTM)$-0.02
ROE0.44%
Fundamental Analysis

AI Price Forecasts

1 Week$0.00
1 Month$0.00
3 Months$0.00
1 Year Target$0.00

QBIO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Q BioMed Inc. (QBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 14.5K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for QBIOStats details for QBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for QBIOAnalyst Recommendations details for QBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

CEO

Denis D. Corin

Employees

3

Headquarters

366 Madison Avenue, New York City, NY

Founded

2015

Frequently Asked Questions

;